Christopher A. Chamberlain
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 17
- Cancer Immunotherapy and Biomarkers 10
- CAR-T cell therapy research 7
- Pancreatic and Hepatic Oncology Research 3
-
- Immunotherapy and Immune Responses 8
- Immune Cell Function and Interaction 5
- Co-authors
- Marco Donia (18 shared papers)Inge Marie Svane (17 shared papers)Özcan Met (9 shared papers)Kasper Mølgaard (1 shared paper)Arianna Draghi (13 shared papers)Eric Bennett (2 shared papers)Anders Kverneland (4 shared papers)Troels Holz Borch (5 shared papers)
In The Last Decade
Christopher A. Chamberlain
21 papers receiving 589 citations
Peers
Comparison fields: 5 of 62
- Oncology 388
- Immunology 260
- Aging 5
- Business and International Management 5
- Molecular Biology 158
Countries citing papers authored by Christopher A. Chamberlain
This map shows the geographic impact of Christopher A. Chamberlain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Chamberlain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Chamberlain more than expected).
Fields of papers citing papers by Christopher A. Chamberlain
This network shows the impact of papers produced by Christopher A. Chamberlain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Chamberlain. The network helps show where Christopher A. Chamberlain may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher A. Chamberlain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 162 | |
| 2 | 2020 | 64 | |
| 3 | 2022 | 57 | |
| 4 | 2018 | 52 | |
| 5 | 2021 | 50 | |
| 6 | 2018 | 37 | |
| 7 | 2018 | 36 | |
| 8 | 2022 | 26 | |
| 9 | 2020 | 25 | |
| 10 | 2021 | 16 | |
| 11 | 2021 | 15 | |
| 12 | 2023 | 13 | |
| 13 | 2020 | 12 | |
| 14 | 2022 | 10 | |
| 15 | 2018 | 8 | |
| 16 | 2021 | 6 | |
| 17 | 2022 | 4 | |
| 18 | 2019 | 2 | |
| 19 | 2025 | 1 | |
| 20 | 2020 | 1 |
About Christopher A. Chamberlain
Christopher A. Chamberlain is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Microbiology, having authored 22 papers that have together received 598 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (5 papers), Virus-based gene therapy research (5 papers), Pancreatic and Hepatic Oncology Research (3 papers), CRISPR and Genetic Engineering (3 papers) and Antimicrobial Peptides and Activities (2 papers). The work is most often cited by research in Oncology (388 citations), Immunology (260 citations), Aging (5 citations), Business and International Management (5 citations) and Molecular Biology (158 citations). Christopher A. Chamberlain has collaborated with scholars based in Denmark, Hungary and Sweden. Frequent co-authors include Marco Donia, Inge Marie Svane, Özcan Met, Kasper Mølgaard, Arianna Draghi, Eric Bennett, Anders Kverneland, Troels Holz Borch, Morten Nielsen and Andrew J.S. Furness. Their work appears in journals such as Annals of Oncology, Seminars in Immunopathology, Cancer Immunology Immunotherapy, Clinical Cancer Research and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.